Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV004799358 | SCV001431211 | uncertain significance | Intellectual disability-hypotonia-spasticity-sleep disorder syndrome | 2019-12-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001879929 | SCV002317648 | uncertain significance | not provided | 2022-05-25 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available"). ClinVar contains an entry for this variant (Variation ID: 977447). This variant has not been reported in the literature in individuals affected with ANK3-related conditions. This variant is present in population databases (rs746416574, gnomAD 0.006%). This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 1163 of the ANK3 protein (p.Gln1163Arg). |
Ambry Genetics | RCV004035348 | SCV004898413 | uncertain significance | Inborn genetic diseases | 2023-12-15 | criteria provided, single submitter | clinical testing | The c.3488A>G (p.Q1163R) alteration is located in exon 29 (coding exon 29) of the ANK3 gene. This alteration results from a A to G substitution at nucleotide position 3488, causing the glutamine (Q) at amino acid position 1163 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |